Logo

Merck Reports Data from the P-III (STRIDE-10) Trial of V116 Pneumococcal Conjugate Vaccine for Adults

Share this
Merck

Merck Reports Data from the P-III (STRIDE-10) Trial of V116 Pneumococcal Conjugate Vaccine for Adults

Shots:

  • The P-III (STRIDE-10) trial assessed the immunogenicity, tolerability and safety of V116 vs PPSV23 in adults (n=1,484, 50yrs. & above) not receiving pneumococcal vaccine before
  • The study depicted non-inferior immune responses with V116 for the 12 shared serotypes with PPSV23, superior immune responses for the 9 serotypes unique to V116 & superior immune responses for 8/9 serotypes unique to V116 as evaluated by the proportions of patients with ≥4-fold rise
  • Furthermore, V116’s review by the US FDA & the EMA is currently underway. The drug also received the US FDA’s priority review with the decision anticipated in Jun 2024

Ref: Merck | Image: Merck

Related News:- Merck Highlights Results from Various P-III Trials of V116 Vaccine for Pneumococcal Diseases at ISPPD-13 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions